Back to top

vaccines: Archive

Zacks Equity Research

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.

NVOPositive Net Change EBSPositive Net Change PBYINegative Net Change CTMXPositive Net Change

Zacks Equity Research

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study

Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.

GSKNegative Net Change PFEPositive Net Change NVOPositive Net Change MRKPositive Net Change

Zacks Equity Research

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

AZNPositive Net Change PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change